- Press Releases
- Notices
Press Releases To List
-
- Dec.11.2025Sustainability
- Ono Receives Highest A-List Rating in CDP 2025 Report for Climate Change and Water Security Efforts
-
- Dec.08.2025R & D
- Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
-
- Nov.20.2025R & D
- Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
-
- Nov.11.2025R & D
- Updated Global Phase 1/2 Clinical Trial Data for Povetacicept, which was Granted Breakthrough Therapy Designation in IgA Nephropathy and Fast Track Designation in Primary Membranous Nephropathy from FDA
-
- Oct.31.2025Corporate
- Notice on the Recipients of the “Osamu Hayaishi Memorial Scholarship for Study Abroad” of the FY2026 Japanese Biochemical Society
Notices To List
-
- Nov.04.2025Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q2 - Script
-
- Sep.29.2025Corporate
- Corporate Report 2025 has been released.
-
- Aug.04.2025Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q1 - Script
-
- Jun.20.2025Corporate
- Voting Results (Extraordinary Report) of the 77th Ordinary General Shareholders’ Meeting
-
- Jun.19.2025Corporate
- Notice to Resolutions Passed at The 77th Ordinary General shareholders’ Meeting
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
